Doctors at Vanderbilt University Medical Center, Nashville, USA, identified the monoclonal antibody C225 as a potential treatment, after spending 10 years studying the role of epidermal growth-factor receptor in the development of the disease.
The 48-year-old patient from Texas, USA, was referred to Nashville showing symptoms of repeated vomiting. Because he also had lung disease, surgery to remove the stomach and prevent progression to cancer was not possible.
Anti-epidermal growth factor helps Ménétrier's disease
The hospital gained approval from the US Food and Drug Administration for compassionate use of C225 for one month.
After treatment with the drug, the patient's repeated vomiting stopped, there was a reduction in proliferation of gastric surface mucous cells, and an increase in levels of gastrin.
The doctors gained no information about the potential long-term effects of the treatment, because it ended when the patient suffered a fatal heart attack as he underwent evaluation for a heart-lung transplant.
Researcher Professor Robert Coffey said, "This really takes us from bench to bedside and back.
"It's very gratifying to have worked in an area for more than 10 years, plugging along, and then be able to implicate a pathway that is important in the pathogenesis of a human disease."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com